PET-detected pneumonitis following curative-intent chemoradiation in non-small cell lung cancer (NSCLC): recognizing patterns and assessing the impact on the predictive ability of FDG-PET/CT response assessment.


Journal

European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988

Informations de publication

Date de publication:
Aug 2019
Historique:
received: 09 03 2019
accepted: 31 05 2019
pubmed: 14 6 2019
medline: 24 7 2020
entrez: 14 6 2019
Statut: ppublish

Résumé

Inflammatory FDG uptake in the lung (PET-pneumonitis) following curative-intent radiotherapy (RT)/chemo-RT (CRT) in non-small cell lung cancer (NSCLC) can pose a challenge in FDG-PET/CT response assessment. The aim of this study is to describe different patterns of PET-pneumonitis to guide the interpretation of FDG-PET/CT and investigate its association with tumor response and overall survival (OS). Retrospective analysis was performed on 87 NSCLC patients in three prospective trials who were treated with radical RT (n = 7) or CRT (n = 80), with baseline and post-treatment FDG-PET/CT. Visual criteria were performed for post-treatment FDG-PET/CT response assessment. The grading of PET-pneumonitis was based on relative lung uptake intensity compared to organs of reference and classified as per Deauville score from grade 1-5. Distribution patterns of PET-pneumonitis were defined as follows: A) patchy/sub-pleural; B) diffuse (involving more than a segment); and C) peripheral (diffusely surrounding a photopenic region). Follow-up FDG-PET/CT scans were performed approximately 3 months (median, 89 days; interquartile range, 79-93) after RT. Overall, PET-pneumonitis was present in 62/87 (71%) of patients, with Deauville 2 or 3 in 12/62 (19%) and 4 or 5 in 50/62 (81%) of patients. The frequency of patterns A, B and C of PET-pneumonitis was 19/62 (31%), 20/62 (32%) and 23/62 (37%), respectively. No association was found between grade or pattern of PET-pneumonitis and overall response at follow-up PET/CT (p = 0.27 and p = 0.56, respectively). There was also no significant association between PET-pneumonitis and OS (hazard ratio [HR], 1.3; 95% confidence interval [CI], 0.6-2.5; p = 0.45). Early FDG-PET/CT response assessment, however, was prognostic for OS (HR, 1.7; 95% CI, 1.2-2.2; p < 0.001). PET-pneumonitis is common in early post-CRT/RT, but pattern recognition may assist in response assessment by FDG-PET/CT. While FDG-PET/CT is a powerful tool for response assessment and prognostication, PET-pneumonitis does not appear to confound early response assessment or to independently predict OS.

Identifiants

pubmed: 31190177
doi: 10.1007/s00259-019-04388-3
pii: 10.1007/s00259-019-04388-3
doi:

Substances chimiques

Fluorodeoxyglucose F18 0Z5B2CJX4D

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1869-1877

Auteurs

Amir Iravani (A)

Cancer Imaging, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, VIC, 3000, Australia. amir.iravani@petermac.org.
Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia. amir.iravani@petermac.org.

Guy-Anne Turgeon (GA)

Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

Tim Akhurst (T)

Cancer Imaging, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, VIC, 3000, Australia.

Jason W Callahan (JW)

Cancer Imaging, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, VIC, 3000, Australia.

Mathias Bressel (M)

Department of Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

Sarah J Everitt (SJ)

Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
Radiation Therapy, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Department of Medical Imaging and Radiation Sciences, Faculty of Medicine and Dentistry, Monash University, Clayton, VIC, Australia.

Shankar Siva (S)

Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

Michael S Hofman (MS)

Cancer Imaging, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, VIC, 3000, Australia.

Rodney J Hicks (RJ)

Cancer Imaging, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, VIC, 3000, Australia.
Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.

David L Ball (DL)

Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

Michael P Mac Manus (MP)

Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH